If we have selected the wrong experience for you, please change it above.
Biotech commercialization strategies: New science, new stakes
How new science, investment, and AI in life sciences are reshaping biotech launch success
Emerging companies are rewriting the rules by investing smarter, not just bigger. In this crowded field, how can lean organizations compete? Explore how a modern playbook for biopharma commercialization can transform a strong asset into sustained market performance.
Key takeaways
- First-launch biotechs are entering more scientifically and commercially complex territory.
- Rising scientific complexity is reshaping what commercialization requires and what it costs.
- First-launch success rates have improved, reflecting a more disciplined understanding of when and where investment creates commercial impact.
- Against a more demanding launch environment, how companies finance independent commercialization is becoming a more strategic question.
- Artificial intelligence (AI) may begin to shift what lean commercial organizations can realistically execute.
The new rules of biotech commercialization
The complex territory challenges of first-launch biotechs
Over the past 15 years, launches grew in sophistication, especially in oncology and novel therapeutics. Many enter areas lacking commercial precedent. Thus, life sciences commercial operations must build patient pathways alongside the biopharma product launch itself. Market shaping is about building an audience that doesn’t yet exist, not reaching an established one.
Reshaping commercialization requirements and costs
Median pre-launch selling, general, and administrative (SG&A spend for first-launch biotechs) reached $142 million. Novel modalities like cell and gene therapies carried a $190 million median, compared to $110 million for traditional ones. A successful biotech commercialization strategy must address this rising complexity, as modern biopharma commercialization requires building specialized infrastructure to enable the market.
Understanding when and where investment creates commercial impact
First-launch success rates climbed from 60% in 2011 to over 80% in 2015. Successful launchers invested more pre-launch, diverging 18 months before approval. A winning biotech commercialization strategy relies on this earlier commitment to execution milestones, proving that early investment is a meaningful differentiator in modern life sciences commercialization.
How companies finance independent commercialization
As traditional equity and debt became more expensive, a separate Deloitte analysis showed royalty financing volume more than doubled between 2015 to 2019 and 2020 to 2024 periods. A modern biotech commercialization strategy increasingly leverages these non-dilutive instruments. Securing them relies heavily on asset quality and a highly credible plan for biopharma commercialization.
Artificial intelligence (AI) could shift lean commercial organizations’ execution
For lean biotechs, Deloitte estimates commercial functions drive 25% to 35% of total value for AI in life sciences. Rather than replacing talent, emerging biotechs can design AI-enabled workflows from the outset. This structural flexibility allows them to optimize their life sciences commercial operations and execute highly targeted launches.
Get in touch
Deepak Singla Kriti Wahi Akanxa Swami
desingla@deloitte.com krwahi@deloitte.com akaswami@deloitte.com
Mathias Cousin Teresa Leste
mcousin@deloitte.com tleste@deloitte.com
